Precision Cancer Therapy in Rare Cancers

• Status: Not yet recruiting
• Trial end date: 2033-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Collaborators: Haukeland University Hospital; Helse Fonna; Helse Forde; Helse Nord-Trøndelag HF; Helse Stavanger HF; Møre og Romsdal Hospital Trust; Nordlandssykehuset HF; Sorlandet Hospital HF; StOlavs Hospital; Sykehuset Innlandet HF; Sykehuset Ostfold; The Hospital of Vestfold; University Hospital of North Norway
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• ECOG 0-2,

• identified biomarker,

• reasonable biochemistry

Exclusion Criteria:

• ECOG 3-5

• serious other diseases